A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 in Healthy Adult Subjects

An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period, Crossover Study to Evaluate the Safety and the Pharmacokinetics of AD-118 Compared to AD-1181 in Healthy Adult Volunteers

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07476157

Enrollment

Registered

2026-03-17

Start date

2026-04-01

Completion date

2026-05-01

Last updated

2026-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure

Brief summary

A Study to Evaluate the Safety and Pharmacokinetics of AD-118 and AD-1181 Under Fasted Conditions in Healthy Adult Subjects

Interventions

DRUGAD-118, AD-1181

Single-dose oral administration of AD-118 or AD-1181, according to randomized sequence.

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 64 Years

Healthy volunteers

Yes

Inclusion criteria

* Body weight equal to or greater than 50kg and Body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit * Subjects aged 19 years or older and under 65 years at the screening visit

Exclusion criteria

* Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration * Other exclusions applied

Design outcomes

Primary

Measure	Time frame	Description
Area under the plasma concentration-time curve during dosing interval (AUCt)	pre-dose (0hour) to 36hours	AUCt of AD-118
Maximum concentration of drug in plasma (Cmax)	pre-dose (0hour) to 36hours	Cmax of AD-118

Countries

South Korea

Contacts

CONTACTJaeHun Jung

jhjung@addpharma.co.kr+82-31-891-5683

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026